**Germany Paves the Way for a Revolutionary Cannabis-Based Painkiller**
In a groundbreaking development for the medical world, Germany has just marked a significant milestone in the ongoing quest for effective pain management. The country’s Federal Institute for Drugs and Medical Devices recently gave the green light to Exelb, the first-ever cannabis-derived oral tincture aimed specifically at treating chronic pain. Created by pharmaceutical company Vertanle, Exelb is set to hit the market this fall, potential turning heads and alleviating much pain as it enters the arena traditionally dominated by opioids.
Clemens Fischer, the bald-headed, 50-year-old billionaire behind Vertanle, has taken on quite the feat to bring Exelb to life. He’s akin to a David in a world full of Goliaths — battling for a place in a market where over 20 million opioid prescriptions flood Germany each year. With between 6 and 7 million patients possibly seeking alternatives, the timing for Exelb couldn’t be better. During clinical trials, Exelb outperformed both a placebo and traditional opioids, raising hopes for a safer, non-addictive pain management option. Just imagine: a world where patients aren’t constantly looking over their shoulders for the lurking dangers of addiction! Instead, they could be well on their way to feeling better with a cannabis-derived solution.
But what exactly does Fischer envision for Exelb? He’s aiming high — very high. Fischer dreams of capturing at least 10% of the opioid market share, which might not seem ambitious to some, but considering the opioid crisis touching lives everywhere, it’s no small feat. This drive is not limited to Germany. With plans already underway to seek approvals in neighboring Austria and even in the United Kingdom, Vertanle could pave the way for a new era of pain management across Europe. According to Fischer, the ultimate prize is the American market, where around 120 million opioid prescriptions are dished out each year.
Fischer’s journey from a former medical doctor to the CEO of a thriving pharmaceutical empire is a tale worth telling. It all started in 2017, when he stumbled upon news about the burgeoning cannabis industry in the United States. Naturally, curious as ever, he traveled to California and Nevada, immersing himself in the world of medical marijuana. By the time he returned to Europe, he had ordered 500 marijuana seeds, turning a greenhouse originally intended for roses into a 215,000-square-foot cannabis nursery. Talk about a career pivot!
With more than $300 million of his own money invested in this venture, Fischer is not just a businessman — he’s a risk-taker determined to change the course of pain treatment. Alongside his business partner, Madena Holofldderelder, he has dedicated himself to perfecting Exelb, utilizing a strain he calls DKJ127, rich in THC, CBD, and the cannabinoid CBN. This innovative strain aims to provide a level of pain relief without the associated risks of overdose and addiction that have become synonymous with opioids. As the demand for effective, non-addictive pain relief options grows, the spotlight is on Fischer and Vertanle to deliver a solution that many believe could save countless lives.
In a world where the opioid epidemic has overshadowed the medical community’s efforts to find safer alternatives, Exelb symbolizes hope. With the FDA designating it as a “breakthrough therapy” and phase three clinical trials set to begin in the U.S. this summer, the stakes couldn’t be higher. As the clock ticks down to Exelb’s market debut, many are watching closely — eager to see if this cannabis-based painkiller can deliver on its promises and change the landscape of pain management forever. Who knew a little plant had such monumental potential?
